Burlington-based Dyax Corp. said Thursday that it is partnering with a Colombian company that will develop and commercialize its hereditary angiodema treatment in such Latin American countries as Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela.
The strategic partnership is with Novellus Biopharma AG of Bogota. Dyax’s press release did not include financial details of the partnership agreement.
According to Dyax’s website, hereditary angioedema, or HAE, is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is estimated to affect 1 in 10,000 to 1 in 50,000 individuals.
In the United States, Dyax makes a drug called Kalbitor for the treatment of acute attacks of HAE in patients 16 years of age and older.
“Under the terms of the exclusive license agreement, Dyax will receive an upfront payment and is eligible to receive future sales milestones,” the company’s press release said. “Dyax is also eligible to receive royalties on net product sales. Novellus is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of Kalbitor in the covered territories. Additionally, Novellus will purchase drug product from Dyax on a cost-plus basis for commercial supply.”
In a statement, Gustav Christensen, president and chief executive of Dyax, added, “Novellus’ experience in bringing novel biotherapeutics to market will be important in delivering Kalbitor to HAE patients in this region. We continue to make strides in expanding the availability of Kalbitor and delivering an acute HAE treatment to patients in need around the globe.”